138 related articles for article (PubMed ID: 17460930)
1. [Tuberculosis among patients treated with TNF-alpha blockers].
Fuchs-Polychuck I; Avnon LS; Abu-Shakra M
Harefuah; 2007 Mar; 146(3):212-8, 245. PubMed ID: 17460930
[TBL] [Abstract][Full Text] [Related]
2. TNF-alpha blockade and tuberculosis: better look before you leap.
Arend SM; Breedveld FC; van Dissel JT
Neth J Med; 2003 Apr; 61(4):111-9. PubMed ID: 12852719
[TBL] [Abstract][Full Text] [Related]
3. [Recommendations for the diagnosis and treatment of latent and active tuberculosis in patients with inflammatory joint diseases treated with tumour necrosis factor alpha inhibitors].
Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
Acta Reumatol Port; 2006; 31(3):237-45. PubMed ID: 17094335
[TBL] [Abstract][Full Text] [Related]
4. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
Theis VS; Rhodes JM
Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
[TBL] [Abstract][Full Text] [Related]
5. [Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonist drugs].
Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
Rev Port Pneumol; 2006; 12(5):603-13. PubMed ID: 17117328
[TBL] [Abstract][Full Text] [Related]
6. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
Winthrop KL
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
[TBL] [Abstract][Full Text] [Related]
7. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
Wallis RS
Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update.
Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E
Acta Reumatol Port; 2008; 33(1):77-85. PubMed ID: 18344925
[TBL] [Abstract][Full Text] [Related]
9. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.
Keane J
Rheumatology (Oxford); 2005 Jun; 44(6):714-20. PubMed ID: 15741198
[TBL] [Abstract][Full Text] [Related]
10. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies.
Keane J; Bresnihan B
Curr Opin Rheumatol; 2008 Jul; 20(4):443-9. PubMed ID: 18525359
[TBL] [Abstract][Full Text] [Related]
11. Infectious complications of tumor necrosis factor blockade.
Wallis RS
Curr Opin Infect Dis; 2009 Aug; 22(4):403-9. PubMed ID: 19491672
[TBL] [Abstract][Full Text] [Related]
12. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay.
Dinser R; Fousse M; Sester U; Albrecht K; Singh M; Köhler H; Müller-Ladner U; Sester M
Rheumatology (Oxford); 2008 Feb; 47(2):212-8. PubMed ID: 18208824
[TBL] [Abstract][Full Text] [Related]
14. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
15. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
Diel R; Hauer B; Loddenkemper R; Manger B; Krüger K
Pneumologie; 2009 Jun; 63(6):329-34. PubMed ID: 19517358
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.
Denis B; Lefort A; Flipo RM; Tubach F; Lemann M; Ravaud P; Salmon D; Mariette X; Lortholary O;
Clin Microbiol Infect; 2008 Feb; 14(2):183-6. PubMed ID: 18076664
[TBL] [Abstract][Full Text] [Related]
17. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.
Domm S; Cinatl J; Mrowietz U
Br J Dermatol; 2008 Dec; 159(6):1217-28. PubMed ID: 18945310
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostics of latent tuberculosis (TB) in adult vaccinated patients (BCG) in Croatia before introduction of tumor necrosis factor antagonist therapy].
Popović-Grle S; Babić-Naglić D
Reumatizam; 2008; 55(1):31-5. PubMed ID: 19024268
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary infectious complications of tumor necrosis factor blockade.
Wallis RS; Schluger NW
Infect Dis Clin North Am; 2010 Sep; 24(3):681-92. PubMed ID: 20674798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
